About: Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 11 September 2018

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 2018 (uk) article scientifique publié en 2018 (fr) artículu científicu espublizáu en setiembre de 2018 (ast) scientific article published on 11 September 2018 (en) 2018 թվականի սեպտեմբերի 11-ին հրատարակված գիտական հոդված (hy)
publication date	wds:Q91381898-14FF2555-AE66-4C01-A35B-49A1BA5EE9AD
publication date	2018-09-11 00:00:00Z (xsd:dateTime)
cites work	wds:Q91381898-0101863D-874A-4E98-9289-ADF9D5494208 wds:Q91381898-159EDAD4-DC35-49D5-9032-823AB60388FE wds:Q91381898-170F3037-BBD6-41B9-A180-7446D2AE3DC8 wds:Q91381898-2753B229-4437-49DF-A202-DF48712C7CA2 wds:Q91381898-2AF61A68-4282-4FCE-995D-B0C491D3D171 wds:Q91381898-2FFC144B-2159-4D19-B277-F4FDC161DD42 wds:Q91381898-310FD2F7-0B9F-4B07-9D93-55AB327AA31D wds:Q91381898-4871022D-CD96-4F87-A9DC-9F3760E3213D wds:Q91381898-4C23CD1E-A208-4F19-984A-9B451EB7C442 wds:Q91381898-4EEF00DD-86D3-4EBF-B5D9-B49081E7C325 wds:Q91381898-56102845-7FEE-4993-9C28-D65C4CDD5796 wds:Q91381898-7BAAE821-8A12-4DC3-B40C-939E9B1A6CA6 wds:Q91381898-8CF2AACC-11A1-48D3-805B-0E709ED3120C wds:Q91381898-97BB6811-AE8D-4578-B4C9-A7A406C2FCBC wds:Q91381898-BC26E317-ACE8-4F97-AE35-D35EC861C49E wds:Q91381898-BF9BB33C-273F-4E9E-8BA5-91920411F29B wds:Q91381898-D6E415ED-41F8-407F-A9B8-5D9B8B01F63B
cites work	Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma IMWG consensus on risk stratification in multiple myeloma Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma Cancer statistics, 2016 Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis.
author name string	wds:Q91381898-2416BCB8-C5FB-4553-BE18-E621CC9A8083 wds:Q91381898-2AB22C19-47E5-4168-97C7-9E8C4FF2AEAB wds:Q91381898-3904C622-0567-4C0F-8350-3405A3CF770C wds:Q91381898-45C2553E-B568-41B6-90E9-53A6B90CB1D2 wds:Q91381898-63BC9BED-8B39-4CF2-A08A-4D08A89E26E7 wds:Q91381898-8D3527CF-5BD1-4ED7-9426-D5507A61610E wds:Q91381898-B3AAA77F-BD43-4E39-ACEE-F11E7312C3A4 wds:Q91381898-B68B68A8-435B-4403-8AAB-45FA552C586E wds:Q91381898-BB183771-5D5B-4808-AF05-C9B13BDAA6DF wds:Q91381898-CBD5A857-E9C3-4EA7-8B79-CCEA6DFCFD11
author name string	Sagar Lonial Oumar Sy Clara Chen Meletios A Dimopoulos Miriam L Zichlin Dinara Makenbaeva Alexander Brun James E Signorovitch Keith A Betts Sabeen Mekan
rdfs:label	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial (en) Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial (nl)
skos:prefLabel	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial (en) Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial (nl)
name	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial (en) Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial (nl)
author	wds:Q91381898-BC18C6D9-C4F7-41B2-A9B0-863D3A42CE58 wds:Q91381898-C8D3A375-5CD2-448A-92CE-545C2B1C2C46
author	Paul G. Richardson Katja Weisel
title	wds:Q91381898-55FB4A97-1712-4E52-9099-E83214AD25BC
title	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial (en)
page(s)	wds:Q91381898-4CF80384-6AAC-443A-9A85-3EAD07106421
page(s)	4032-4043
instance of	wds:Q91381898-C32F30EA-75B8-41DE-B9E5-9FB5E16B04C8
instance of	scholarly article
main subject	wds:Q91381898-FC263B13-CD7F-401F-8484-FCC08864ED1A wds:Q91381898-FED07CD3-B7E3-4E40-B4CD-FA5DD67939C8
main subject	wd:Q422252 multiple myeloma
PubMed ID	wds:Q91381898-E4D07AB6-7117-4692-9863-E66A70B820EB
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30204239
PubMed ID	30204239
published in	wds:Q91381898-9C7E0173-1435-4CE5-AD5E-FECBCCED578A
published in	Cancer
issue	wds:Q91381898-648850B4-41BE-4D79-A178-0D6BF1048C7C
volume	wds:Q91381898-46DDF07B-BC04-475D-B940-CA95192C390A
issue	20
volume	124
DOI	wds:Q91381898-2E8E1BE2-AE64-4387-97A4-5BFC6345EA1A
DOI	http://dx.doi.org/10.1002/CNCR.31680
DOI	10.1002/CNCR.31680
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q91381898
is cites work of	EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software